Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) $ in Thousands |
3 Months Ended | 6 Months Ended |
|---|---|---|
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2023
USD ($)
|
|
| Deferred Royalty Obligation [Line Items] | ||
| Non-cash interest expense on deferred royalty obligation | $ 400 | $ 442 |
| Percentage of interest rate amortize liability | 16.30% | 16.30% |
| Blackstone Life Sciences | ||
| Deferred Royalty Obligation [Line Items] | ||
| Upfront payment received | $ 140,000 | |
| Blackstone Life Sciences | Maximum | ||
| Deferred Royalty Obligation [Line Items] | ||
| Milestone payment receivable | 250,000 | |
| 2015 License Agreement | Blackstone Life Sciences | ||
| Deferred Royalty Obligation [Line Items] | ||
| Transaction costs incurred | 3,800 | |
| 2015 License Agreement | Blackstone Life Sciences | Royalty | ||
| Deferred Royalty Obligation [Line Items] | ||
| Upfront payment received | $ 140,000 | |
| Revenue interest percentage | 4.00% |
| X | ||||||||||
- Definition Deferred royalty obligation. No definition available.
|
| X | ||||||||||
- Definition Milestone payment receivable. No definition available.
|
| X | ||||||||||
- Definition Non cash interest expense on deferred royalty obligation. No definition available.
|
| X | ||||||||||
- Definition Percentage of interest rate amortize liability No definition available.
|
| X | ||||||||||
- Definition Revenue interest percentage. No definition available.
|
| X | ||||||||||
- Definition Transaction costs incurred. No definition available.
|
| X | ||||||||||
- Definition Upfront payment received. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|